ROS1-Targeted Therapy in Non-Small Cell Lung Cancer.

摘要

H&O What is ROS1, and what is its mechanism of action? LS ROS1 is a receptor tyrosine kinase of the insulin receptor family. Chromosomal rearrangement is the primary mechanism that activates ROS1 in lung cancer and other cancers, and a number of ROS 1 rearrangements can occur in nonsquamous lung cancer. These rearrangements lead to aberrant expression of ROS 1 and constitutive activation of its tyrosine kinase. Signaling downstream of ROS 1 fusions results in activation of cellular pathways that are known to be involved in cell growth and proliferation. H&O How common are ROS1 rearrangements in non-small ceil lung cancer (NSCLC)? LS Genomic alterations in ROS1 have previously been noted in gliomas and were first reported in an Asian patient with NSCLC. Subsequent studies have revealed ROS1 translocations in approximately 1-2% of patients with NSCLC. However, litde is known about the signaling pathway from activated ROS1 kinase.